FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early…
- Investigator
- Torge Rempe
- Ages
- 18 Years - 60 Years
- Sexes
- All